Antagonism of sphingosine 1‐phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct‐ligated rodents
暂无分享,去创建一个
Y. Inoue | K. Koike | H. Ikeda | Y. Yatomi | Y. Okamoto | K. Shinozaki | T. Koyama | H. Yokota | Y. Takuwa | T. Shimosawa | T. Tomiya | Masakazu Nagamine | N. Watanabe | Takako Nishikawa | K. Ishimaru | N. Ohtomo | Yasushi Tanoue | Yumiko Satoh | Mitsuru Yashiro | Y. Kageyama | Yoshika Kusumoto | Natsuko Ohtomo | Y. Kusumoto
[1] S. Spiegel,et al. Conjugated bile acids activate the sphingosine‐1‐phosphate receptor 2 in primary rodent hepatocytes , 2012, Hepatology.
[2] S. Yue,et al. Essential roles of sphingosine 1‐phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation , 2011, Journal of cellular physiology.
[3] Liying Li,et al. Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. , 2011, Journal of hepatology.
[4] S. Salomone,et al. Selectivity and Specificity of Sphingosine-1-Phosphate Receptor Ligands: Caveats and Critical Thinking in Characterizing Receptor-Mediated Effects , 2011, Front. Pharmacol..
[5] H. Nischalke,et al. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis , 2011, Laboratory Investigation.
[6] D. Thabut,et al. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? , 2010, Journal of hepatology.
[7] F. Lammert,et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. , 2010, Journal of hepatology.
[8] Y. Inoue,et al. Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[9] A. Fukamizu,et al. Tumor and Stem Cell Biology Cancer Research S 1 P 2 , the G Protein – Coupled Receptor for Sphingosine-1-Phosphate , Negatively Regulates Tumor Angiogenesis and Tumor Growth In vivo in Mice , 2010 .
[10] H. Katsumi,et al. The effect of wellsolve, a novel solubilizing agent, on the intestinal barrier function and intestinal absorption of griseofulvin in rats. , 2009, Biological & pharmaceutical bulletin.
[11] S. Yue,et al. Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. , 2009, The American journal of pathology.
[12] Hong Wang,et al. Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. , 2009, Journal of hepatology.
[13] T. Sauerbruch,et al. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis , 2009, British journal of pharmacology.
[14] H. Ikeda,et al. Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters , 2008, Annals of clinical biochemistry.
[15] V. Shah,et al. Vascular biology and pathobiology of the liver: Report of a single‐topic symposium , 2008, Hepatology.
[16] T. Sauerbruch,et al. Mechanisms of extrahepatic vasodilation in portal hypertension , 2008, Gut.
[17] F. Lammert,et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats , 2007, Hepatology.
[18] 姉川 剛. Defective endothelial nitric oxide synthase signaling is mediated by Rho-kinase activation in rats with secondary biliary cirrhosis , 2008 .
[19] A. Burroughs,et al. How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. , 2007, Gastroenterology.
[20] F. Nevens,et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and activation of endothelial nitric oxide synthase , 2007, Hepatology.
[21] J. Chun,et al. The sphingosine 1‐phosphate receptor S1P2 triggers hepatic wound healing , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] M. Beaussier,et al. Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries , 2007, Laboratory Investigation.
[23] T. Sauerbruch,et al. Vascular dysfunction in human and rat cirrhosis: Role of receptor‐desensitizing and calcium‐sensitizing proteins , 2007, Hepatology.
[24] T. Sauerbruch,et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis , 2006, Gut.
[25] K. Jakobs,et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. , 2006, Gastroenterology.
[26] A. Dubin,et al. Emerging medicinal roles for lysophospholipid signaling. , 2006, Trends in molecular medicine.
[27] Y. Inoue,et al. Sphingosine 1-phosphate enhances portal pressure in isolated perfused liver via S1P2 with Rho activation. , 2004, Biochemical and biophysical research communications.
[28] J. Chun,et al. Lysophospholipid receptors: signaling and biology. , 2004, Annual review of biochemistry.
[29] E. Goetzl,et al. The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] Y. Inoue,et al. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. , 2003, American journal of physiology. Gastrointestinal and liver physiology.
[31] Y. Inoue,et al. Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5. , 2003, Gastroenterology.
[32] G. Kolios,et al. Isolation of rat Kupffer cells: a combined methodology for highly purified primary cultures , 2003, Cell biology international.
[33] D. Manning,et al. Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. , 2002, Biochimica et biophysica acta.
[34] J. Chun,et al. In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. , 2002, Biochimica et biophysica acta.
[35] N. Ferrentino,et al. Angiotensin receptor antagonists in portal hypertension: fog over paradise. , 2002, Gastroenterology.
[36] H. Nawata,et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. , 2001, Journal of hepatology.
[37] P. Tangkijvanich,et al. Wound‐induced migration of rat hepatic stellate cells is modulated by endothelin‐1 through rho‐kinase‐mediated alterations in the acto‐myosin cytoskeleton , 2001, Hepatology.
[38] H. Ikeda,et al. Biological activities of novel lipid mediator sphingosine 1-phosphate in rat hepatic stellate cells. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[39] H. Nawata,et al. A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. , 2000, Journal of hepatology.
[40] H. Yee,et al. Quantitation of rat hepatic stellate cell contraction: stellate cells' contribution to sinusoidal resistance. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[41] S. Spiegel,et al. Sphingolipid metabolism and cell growth regulation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] H. Ikeda,et al. Cyclosporin A and FK‐506 in inhibition of rat ito cell activation in vitro , 1995, Hepatology.
[43] S. Friedman,et al. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. , 1992, Journal of submicroscopic cytology and pathology.
[44] J. Kountouras,et al. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. , 1984, British journal of experimental pathology.